Samples that are negative for molecular markers should undergo sequencing for the detection of other common biologically relevant mutations in AML including FLT3, KIT, RUNX1, DNMT3A, IDH1, TET2, and ASXL1. Next-generation sequencing (NGS) could possibly identify novel genetic markers in a population specific group and add further value to the results generated by AMLprofiler [19, 20]. This evidence concerns the gene KIT and acute myeloid leukemia.